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Abstract 
Objectives: Heart rate (HR) and systolic blood pressure (SBP) are independent 
prognostic variables in patients with heart failure (HF).  We evaluated if combining HR 
and SBP could  improve prognostic assessment in older patients.  
Methods: Variables associated with all-cause mortality and readmission for HF during 
9 months of follow-up were analyzed from the Spanish Heart Failure Registry (RICA). 
HR and SBP values were stratified in three combined groups.  
Results: We evaluated 1551 patients, 82 years and 56% women. Using HR strata of 
<70 and >= 70 bpm we found mortality rates of 9.8 and 13.6%, respectively (hazard 
ratio 1.0 and 1.35). For SBP >=140, 120-140 and <120 mmHg, mortality rates were 8.2, 
10.4 and 20.3%. respectively (hazard ratio 1.0, 1.34 and 2.76).  Using combined strata 
of HR < 70 bpm and SBP >= 140 mmHg (n=176; low-risk), HR <70 and SBP <140 + 
HR >= 70 and SBP < 120 (n=1089; moderate-risk) and HR >= 70 and SBP < 120 
(n=286; high-risk) we found mortality rates of 4.5%, 11.0% and 24.0%, respectively. 
Multivariate Cox regression for all-cause mortality shows for low-, middle- and high-
risk groups was 1 (reference), 1.93 (95% CI: 0.93 – 3.99, p = 0.077) and 4.32 (95% CI: 
2.04 - 9.14, p < 0.001). BMI, NYHA, MDRD, hypertension and sodium were also 
independent prognostic factors. 
 Conclusions 
The combination provides better risk discrimination than use of HR and SBP alone and 
may provide a simple and reliable tool for risk assessment for older HF patients in 
clinical practice.   
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Introduction 
Heart failure (HF) is a growing public health problem with high prevalence, morbidity 
and mortality especially in older patients 
1
.  A major challenge in the management of 
HF is the availability of reliable and simple tools that enable patients and physicians to 
have a realistic expectation of prognosis, and to guide treatment options.  A number of 
risk models have been proposed obtained mostly through observational studies or 
clinical trials in patients with systolic HF less than 70 years
2-8
. We previously developed 
a risk model from the SENIORS dataset, based on widely available clinical and 
laboratory variables to predict prognosis in ambulant HF more than 70 years 
9
, and have 
recently validated its usefulness in the RICA register of elderly patients with acute HF 
and mostly preserved ejection fraction 
10
. 
Heart rate (HR) and systolic blood pressure (SBP) are powerful prognostic factors. 
Increased HR or lower SBP are independently associated with higher risk of morbidity 
and mortality 
11, 12
.  As HR and SBP are established as important prognostic variables, 
combining these factors could improve risk assessment compared to using them 
individually.  We assessed the value of the combination of SBP and HR in the 
prognostic stratification of elderly patients with heart failure in a “real world|” clinical 
setting. 
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Methods 
Patients were included from the multicentre prospective RICA registry, coordinated by 
the Working Group of Heart Failure of the Spanish Society of Internal Medicine 
12, 13
. 
This registry includes data from public and private hospitals in Spain, and was approved 
by the Ethics Committee of the Hospital University Reina Sofia in Córdoba. From 
March 2008 to September 2013, a total of 3054 patients, consecutively admitted to 
Internal Medicine units with acute decompensated HF from 52 centres, were enrolled. 
In addition to giving their informed consent, patients were recruited if they were ≥ 50 
years old with HF diagnosed according to the criteria of the European Society of 
Cardiology 
14
. Data were collected through a secure website (www.registrorica.org). The 
registry recorded demographic data, blood pressure, heart rate (HR), body weight and 
height, atrial fibrillation (AF), ejection fraction, co-morbidities, functional status, 
routine laboratory data, complications during admission and prescriptions at discharge. 
Follow-up consisted of two mandatory visits scheduled at 3 months and at 1 year, where 
new hospitalizations or deaths were recorded. 
In this analysis we collected baseline information 3 months after discharge for acute HF 
to avoid clinical instability, and outcomes were evaluated in those patients  70 years 
old with at least a follow-up of 12 months from discharge (average of 9 months follow 
up). Main outcome was all-cause (AC) mortality. Secondary end-points were HF 
readmission or the composite of AC mortality or HF readmission. 
Statistical analysis. 
For SBP the cutoffs point were based on the tertiles of the sample (120 and 140 bpm) 
and in the case of HR the cutoff point resulted to be the same that in the BEAUTIFUL 
study (70 bpm) 
15 
to analyse the risk pattern using hazard ratios and 95% confidence 
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intervals (CI).  We then combined HR and SBP in three clinically relevant groups: 
“low-risk” (HR < 70 bpm & SBP >= 140 mmHg), “moderate-risk” (HR < 70 bpm & 
SBP < 140 mmHg + HR >= 70 bmp & SBP >= 120 mmHg), and “high-risk” (HR >= 70  
bpm & SBP < 120 mmHg). We developed Kaplan-Meier curves and Cox proportional 
hazard models to compare risk for each group, both in all patients and those with sinus 
rhythm. We constructed the following 2 Cox proportional hazard models; a) unadjusted, 
b) fully adjusted for age, sex, clinical status, comorbidity and medications. We included 
the following covariates which potentially influence the outcomes: age, sex, SBP, 
diastolic blood pressure (DBP), HR, NT-proBNP, sodium, beta-blocker, body mass 
index (BMI), New York Heart Association (NYHA) class, glomerular filtration rate 
measured by the modification of diet in renal disease (MDRD) formula, diabetes, 
digoxin, AF, left ventricular ejection fraction (LVEF), acenocumarol and haemoglobin. 
The multivariate analysis was performed using the stepwise model, selecting those 
variables with a statistical p significance < 0.10 in the univariate analysis 
Statistical analysis was performed using SPSS Statistics 21.0 (SPSS Inc, Chicago, IL, 
USA). Statistical significance was defined P-value less than 0.05. 
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Results 
Patients 
A total of 1551 patients were included with mean age was 82 years and 56 % were 
women. Patients were divided into three groups according to their risk based on the 
combined HR and SBP groups; low-risk  (n: 176) moderate risk (n: 1089) and high-risk 
(n:286).  At final follow-up 191 patients had died (12.3%), 191 were readmitted 
(12.0%), and 360 (23%) were readmitted or dead.  
Baseline clinical characteristics 3 months after discharge, overall and in the combined 
HR & SBP strata risk subgroups are shown in Table 1.  NYHA III class, AF,  NT-
proBNP and use of spironolactone were associated with high-risk group, while diabetes, 
BMI and serum sodium with low-risk group. There were no apparent differences in 
comorbidities,  LVEF and other clinical and biological data.  
Mortality using HR and SBP alone. 
Using HR strata of <70 and >= 70 bpm we found mortality rates of 9.8 and 13.6%, 
respectively (hazard ratio 1.0 and 1.35). For SBP >=140, 120-140 and <120 mmHg, 
mortality rates were 8.2, 10.4 and 20.3%. respectively (hazard ratio 1.0, 1.34 and 2.76).  
Mortality in the three risk groups combining HR and SBP 
Using combined strata of HR < 70 bpm and SBP >= 140 mmHg (n=176; low risk), HR 
<70 and SBP <140 + HR >= 70 and SBP < 120 (n=1089; moderate  risk) and HR >= 70 
and SBP < 120 (n=286; high risk) we found mortality rates of 4.5%, 11.0% and 24.0%, 
respectively from 3 months to 12 months after discharge (P<0.001) (Figure 1, Table 2).   
Multivariate Cox regression for all-cause mortality shows for low-, middle- and high-
risk groups was 1 (reference), 1.93 (95% CI: 0.93 – 3.99, p = 0.077) and 4.32 (95% CI: 
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2.04 - 9.14, p < 0.001). BMI, NYHA, MDRD, hypertension and sodium were also 
independent prognostic factors. 
There were no significant differences in readmission rates in the three groups. For the 
composite outcome of HF readmission or AC mortality, rates were 16%, 22% and 34% 
in the low-, moderate- and high-risk groups, respectively (p < 0.001), driven by 
differences in AC mortality (data not shown).   
Mortality in the risk groups combining HR and SBP in patients with sinus rhythm. 
Sinus rhythm was observed in 540 patients (35 % of total) with an overall mortality of 
12%.  In the low-, moderate- and high-risk groups mortality rates were 2.6%, 10% and 
29% (hazard ratio 1.0, 4.0 and 15.9, respectively (p <0.001; Figure 2). The sinus rhythm 
group had similar results to the overall group for readmission and composite of 
readmission or AC mortality (data not shown).  
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Discussion 
This is the first analysis combining information about HR and SBP in elderly patients 
with HF and a great percentage with preserved systolic function and atrial fibrillation, 
showing an improved ability to distinguish low-, moderate- and high-risk groups for all-
cause mortality, compared to each one alone. Our cohort included elderly HF patients 
with high rates of AF and preserved ejection fraction, receiving treatments similar to 
other “real world” registries 
16, 17
.
 
 The simplicity of this risk model could make it easier 
to translate into clinical practice than more complex models.  
Our findings are consistent with another publication combining HR and SBP to predict 
mortality in HF but this was in a younger cohort (mean age 68) and sinus rhythm 
17
. We 
provide further evidence showing that the prognostic value of combining HR and SBP 
is also applicable to older patients with mixed sinus rhythm and AF.  
Previous studies have demonstrated the relationship of increased HR with adverse 
outcomes in HF
 11
.  The mechanisms are not entirely clear but it is possible that 
tachycardia with reduced myocardial contractility leads to deteriorating cardiac output. 
It is possible that the adverse effects of faster HR is different in sinus rhythm vs AF. In 
line with this, a meta-analysis of individual patients data of beta-blockers in HF has 
shown a lack of benefit of beta blockers in patients with AF 
18
. Our study supports this 
finding, since the gradation of mortality risk was higher in patients with sinus rhythm.  
Lower blood pressure has been also established as an adverse prognostic factor in HF 
12 , 
19
. A plausible explanation could be poor tissue perfusion associated with impaired heart 
function and a worse prognosis.  
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In general established risk factors tracked the risk stratification gradient for HR and 
SBP except for diabetes and high BMI which were more frequent in the lower risk 
group which is different to previous observations 
20-22
.  High BMI is associated with a 
better prognosis in HF, and is also associated with diabetes and this may partially 
explain this observation 
23
. 
Several risk models in HF have been developed and validated, using data from 
observational studies and clinical trials, but these have mostly included patients younger 
than 70 years with systolic dysfunction 
24 - 27
. Since HF is a disease predominantly 
affecting the elderly, it would be of importance to have a risk stratification tool specific 
for this patient population. Using the SENIORS cohort, we generate a risk model with a 
number of clinical and laboratory variables in stable HF patients older than 70 years, 
that was validate in another RICA registry study 
9, 10, 29
. Our study using combining only 
two variables, HR and SBP, might add value because it is simpler to use in clinical 
practice.  
Limitations 
The aim was to include HF patients admitted to general internal medicine wards but 
some of the sicker patients were unable to give consent which could have introduced a 
selection bias.  The moderate-risk group is much larger than the lower and high risk 
groups, but we did not think that it could have significantly influence the results. The 
HR and SBP thresholds for each group were selected, arbitrarily, based on previous 
studies, however they work well in our analysis. Finally we have not performed an 
internal validation exercise e.g. partitioning the cohort into derivation and validation 
sample.  Previous experience shows that this approach overestimates the validity of a 
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risk prediction model and the only reliable way to test the usefulness of the model is to 
apply it to a separate cohort ideally prospectively 
9
. 
Conclusions: 
These results suggest that an approach of combining HR and SBP may provide a simple 
and reliable clinical tool for mortality risk assessment in HF that could be used in 
clinical practice in elderly patients.  This approach could also be tested in other cohorts 
and against existing risk models. 
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Tables and figures. 
Table 1. Baseline characteristics at 3 months after Hospital discharge in the overall and 
in the subgroups according strata risk 
Variables 
Total 
(N = 1551) 
Low-risk 
(HR < 70 & 
SBP >= 140) 
(N=176) 
Moderate-risk  
(HR < 70  & 
SBP < 140) + 
(HR >=70 & 
SBP>=120) 
(N=1089) 
High-risk 
(HR >= 70 & 
SBP < 120) 
(N=286) 
p-value 
Age, years (M+SD) 81.5±5.5 81.8±5.6 81.4±5.4 81.8±5.9 0.398 
Sex, Women, n (%) 861 (56%) 93 (53%) 632 (58%) 136 (48%) 0.005 
BMI (M+SD) 28.4±6.5 29.0±5.8 28.6±6.9 27.2±5.0 0.002 
SBP, mmHg (M+SD) 130.8±21.1 153.3±13.3 133.9±17.9 105.2±9.2 <0.001 
DBP, mmHg (M+SD) 71.5±12.7 74.9±11.6 73.1±12.7 63.1±9.4 <0.001 
HR, bpm/min (M+SD) 75.2±13.7 61.6±5.9 75.3±13.3 83.1±11.9 <0.001 
NYHA I, n (%) 206 (13%) 22 (13%) 151 (14%) 33 (12%) 0.545 
HYHA II, n (%) 905 (59%) 112 (64%) 647 (60%) 146 (51%) 0.012 
NYHA III, n (%) 408 (26%) 36 (20%) 274 (25%) 98 (34%) 0.001 
NYHA IV, n (%) 25 (1.6%) 6 (3.4%) 11 (1.0%) 8 (2.8%) 0.014 
Etiology       
Ischemic, n (%) 410 (26%) 58 (33%) 272 (25%) 80 (28%) 0.069 
Hypertensive, n (%) 630 (41%) 72 (41%) 467 (43%) 91 (32%) 0.003 
Valvulopathy, n (%) 285 (18%) 29 (16%) 193 (18%) 63 (22%) 0.196 
Others, n (%) 225 (14.5%) 17 (9.7%) 156 (14%) 52 (18%) 0.039 
Charlson index (M+SD) 2.8±2.4 2.9±2.4 2.7±2.3 2.9±2.5 0.322 
Barthel index (M+SD) 83.9±19.9 84.7±21.2 84.2±19.6 82.5±20.3 0.424 
Diabetes, n (%) 663 (43%) 86 (49%) 475 (44%) 102 (36%) 0.012 
Hypertension, n (%) 1.343 (87%) 158 (90%) 959 (88%) 226 (79%) <0.001 
Prior MI, n (%) 333 (21%) 43 (24%) 220 (20%) 70 (24%) 0.181 
COPD, n (%) 395 (26%) 44 (25%) 256 (24%) 95 (33%) 0.004 
AF, n (%) 866 (56%) 82 (47%) 605 (56%) 179 (63%) 0.004 
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LVEF,% (M+SD) 51.9±14.9 52.5±14.3 52.5±14.7 49.3±15.7 0.005 
LVEF < 40%, n (%) 322 (21%) 31 (18%) 219 (20%) 72 (26%) 0.093 
LVH, n (%) 400 (26%) 50 (30%) 286 (27%) 64 (23%) 0.224 
RBBB, n (%) 190 (12%) 23 (13%) 136 (13%) 31 (11%) 0.690 
LBBB, n (%) 307 (20%) 33 (19%) 199 (18%) 75 (26%) 0.012 
Laboratory (M±SD)      
Hemoglobin (mg/dL) 12.4±3.2 13.0±8.2 12.3±1.7 12.5±1.7 0.057 
Creatinine (mg/dL) 1.3±0.6 1.3±0.6 1.3±0.6 1.4±0.7 0.064 
Sodium (mEq/L) 140.0±4.0 140.8±3.9 139.9±3.9 139.6±4.1 0.006 
GFR(mL/min/1.73 m2) 57.4±24.0 55.9±21.5 57.2±24.1 58.8±24.9 0.424 
GFR <30, n (%)  83 (5.4%) 11 (6.3%) 56 (5.2%) 16 (5.6%) 0.819 
GFR 30-59, n (%) 386 (25%) 51 (29%) 266 (24%) 69 (24%) 0.414 
GFR >=60, n (%) 112 (7.2%) 12 (6.8%) 79 (7.3%) 21 (7.3%) 0.974 
BNP (pg/mL). n = 101 655±935 587±922 563±893 974±1.040 0.196 
NT-proBNP. n = 350 3.672±5.822 2.786±2.863 3.452±5.233 5.001±8.458 0.092 
Treatment:      
Digoxin, n (%) 370 (24%) 36 (20%) 256 (24%) 78 (27%) 0.220 
Loop diuretic, n (%) 1.366 (88%) 160 (91%) 949 (87%) 257 (90%) 0.211 
Beta-blockers, n (%) 859 (55%) 89 (51%) 610 (56%) 160 (56%) 0.394 
ACEI, n (%) 698 (45%) 80 (45%) 481 (44%) 137 (48%) 0.524 
ARBs, n (%) 459 (30%) 53 (30%) 331 (30%) 75 (26%) 0.383 
Anticoagulants 
directs, n (%) 
63 (4.1%) 7 (4.0%) 39 (3.6%) 17 (5.9%) 0.197 
Acenocumarol,  n (%) 750 (48%) 76 (43%) 526 (48%) 148 (52%) 0.201 
Spironolactone, n (%) 420 (27%) 36 (20%) 278 (26%) 106 (37%) <0.001 
CCB, n (%) 294 (19%) 44 (25%) 204 (19%) 46 (16%) 0.056 
Readmission after 9-
months, n (%) 
191 (12%) 21 (12%) 129 (12%) 41 (14%) 0.515 
Readmission or 
mortality at 9-months 
360 (23%) 29 (16%) 235 (22%) 96 (34%) <0.001 
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Mortality at 9-months 191 (12.3%) 8 (4.5%) 115 (11%) 68 (24%) <0.001 
SD: standard deviation; BMI: Body mass index; SBP: systolic blood pressure; DBP: diastolic 
blood pressure; HR: heart rate; NYHA: New York Heart Association; MI: myocardial infarction; 
COPD: chronic obstructive pulmonary disease; AF: atrial fibrillation; LVEF: left ventricular 
ejection fraction; LVH: left ventricular hypertrophy; LBBB: left branch bundle block; RBBB: right 
branch bundle block; GFR: glomerular filtration by MDRD: modification of diet in renal disease; 
ACEI: angiotensin converting enzyme inhibitor; ARBs: angiotensin receptor blockers; CCB: 
calcium cannel-blockers.
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Table 2. All-cause mortality for different combinations of SBP and HR during nine 
months of follow-up 
 
SBP 
(<120 mmHg) 
 
SBP 
(120-140 mmHg) 
 
SBP  
(>=140 mmHg) 
 
HR 
(<70 bpm) 
 
12.9% 
Moderate-risk group 
(n =132) 
12.3% 
Moderate-risk group 
(n = 204) 
4.5% 
 Low-risk group 
(n = 176) 
HR 
(>=70 bpm) 
 
23.8% 
High-risk group 
(n = 286) 
9.5% 
Moderate-risk group 
(n = 380) 
9.9% 
Moderate-risk group 
(n = 373) 
SBP: systolic blood pressure; HR: heart rate. BPM: beats per minute 
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Tabla 3. Univariate and multivariate analysis. Proportional hazards model: all-cause 
mortality at 9-months. 
 Univariate Multivariate 
Variables HR (95% CI) p-value HR (95% CI) p-value 
Low-risk group* 1 (ref.)  1 (ref.)  
Moderate-risk group** 2.29 (1.12-4.69) 0.023 1.93 (0.93-3.99) 0.077 
High-risk group*** 5.76 (2.77-11.99) <0.001 4.32 (2.04-9.14) <0.001 
Age 1.05 (1.02-1.08) <0.001   
Beta blocker 0.71 (0.54-0.95) 0.019   
BMI 0.93 (0.91-0.96) <0.001 0.92 (0.89-0.95) <0.001 
NYHA II 0.43 (0.32-0.58) <0.001   
NYHA III 2.56 (1.93-3.40) <0.001 2.67 (1.94-3.68) <0.001 
NYHA IV 7.72 (4.39-13.58) <0.001 16.78 (9.03-31.17) <0.001 
DBP 0.98 (0.97-0.99) <0.001   
MDRD 0.98 (0.98-0.99) <0.001 0.99 (0.98-1.00) <0.001 
Diabetes 1.07 (0.80-1.42) 0.648   
Digoxin 1.27 (0.93-1.74) 0.131   
AF 0.91 (0.68-1.21) 0.500   
Sex (Man) 1.28 (0.97-1.70) 0.086   
LVEF < 40%  1.43 (1.04-1.96) 0.029   
Anticoagulation 0.72 (0.27-1.94) 0.518   
Hemoglobin 0.81 (0.74-0.88) <0.001   
Hypertension 1.51 (0.92-2.49) 0.104   
Sodium 0.91 (0.88-0.94) <0.001 0.92 (0.90-0.95) <0.001 
CCB 0.95 (0.66-1.38) 0.804   
HR: hazard ratio; CI: confidence interval; * heart rate < 70 bpm and systolic blood pressure >= 
140 mmHg; **heart rate < 70 bpm  & systolic blood pressure < 140 mmHg and heart rate >=70 
bpm &  systolic blood pressure >=120 mmHg; ***heart rate >=70 bpm and systolic blood 
pressure < 120 mmHg; BMI: Body mass index; DBP: diastolic blood pressure; NYHA: New York 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
 
Heart Association; MDRD: modification of diet in renal disease; AF: atrial fibrillation; LVEF: left 
ventricular ejection fraction; CCB: calcium cannel-blockers. 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
 
Legend of the Figures: 
 
Figure 1: Kaplan-Meier curve  for all cause mortality in the whole low-risk (HR <70 bpm 
& SBP> 140 mmHg), moderate-risk (HR 70 - 80 bpm & SBP 140 – 120 mmHg), and 
high-risk groups (HR > 80 bpm and SBP < 120 mmHg); HR: heart rate; SBP: systolic 
blood pressure;  
 
 
 
 
 
Figure 2: Kaplan-Meier curve  for all cause mortality in patients with sinus rhythm; 
low-risk group (HR <70 bpm & SBP> 140 mmHg), moderate-risk group (HR 70 - 80 
bpm & SBP 140 – 120 mmHg), and high-risk group (HR > 80 bpm and SBP < 120 
mmHg)  HR: heart rate; SBP: systolic blood pressure. 
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